SAB Biotherapeutics, Inc. - SABS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 7.3% | 6,627,501 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Joseph Edelman | 7.3% | 6,627,501 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 7.3% | 6,627,501 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Caligan Partners LP | 8.8% | 7,967,207 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | JOHNSON DAVID EDWARD | 8.8% | 7,967,207 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Vivo Opportunity Fund Holdings, L.P. | 9.99% | 22,637,108 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Vivo Opportunity, LLC | 9.99% | 22,637,108 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman Fund, L.P. | 9.99% | 2,286,301 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman, LLC | 9.99% | 2,286,301 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 9.9% | 8,948,170 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 9.9% | 8,948,170 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 9.9% | 8,948,170 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Michael Kramarz | 9.9% | 8,948,170 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Woodline Partners LP | 6.8% | 5,455,355 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BALYASNY ASSET MANAGEMENT L.P. | 9.45% | 7,225,439 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BAM GP LLC | 9.45% | 7,225,439 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 9.45% | 7,225,439 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Dames GP LLC | 9.45% | 7,225,439 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 9.45% | 7,225,439 | View |
| Aug 12, 2026 | SCHEDULE 13G | Adage Capital Management, L.P. | 8.38% | 6,405,553 | View |
| Aug 12, 2026 | SCHEDULE 13G | Robert Atchinson | 8.38% | 6,405,553 | View |
| Aug 12, 2026 | SCHEDULE 13G | Phillip Gross | 8.38% | 6,405,553 | View |
| Aug 10, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G/A | Joseph Edelman | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G | Caligan Partners LP | 10.4% | 7,697,207 | View |
| May 15, 2026 | SCHEDULE 13G | JOHNSON DAVID EDWARD | 10.4% | 7,967,207 | View |
| May 15, 2026 | SCHEDULE 13G | Balyasny Asset Management L.P. | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | BAM GP LLC | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Balyasny Asset Management Holdings LP | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Dames GP LLC | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Dmitry Balyasny | 9.99% | 5,089,939 | View |
| May 01, 2026 | SCHEDULE 13G | Millennium Management LLC | 5.1% | 3,432,153 | View |
| May 01, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 5.1% | 3,432,153 | View |
| May 01, 2026 | SCHEDULE 13G | Israel A. Englander | 5.1% | 3,432,153 | View |
| Mar 23, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.